Previous 10 | Next 10 |
home / stock / srpt / srpt articles
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday. Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA appr...
Wall Street is on track for a lackluster open after the S&P 500’s back-to-back record performances in the first two sessions of the week....
Pfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap...
RBC Capital Markets has downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) as it weighs recent investor feedback, company commentary, and public s...
RBC Capital Markets has downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) as it weighs recent investor feedback, company commentary, and ...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Enbridge Inc. (NYSE:ENB). “I trust that management team,R...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 08:00:00 ET On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy (DMD), Elevidys, from an accelerated approval to a full appro...